We read with great interest the article by Steg et al 1 who report a subgroup analysis of the Occluded Artery Trial (OAT), 2 a randomized study comparing percutaneous coronary intervention (PCI) combined with medical therapy to medical therapy alone in patients with persistently occluded infarct related artery 3 to 28 days after an acute myocardial infarction, in which they assess the relation between angiographically visible collaterals to the infarct related artery territory and clinical outcome and the interaction between collaterals and treatment assignment on outcome.
To the Editor:
We read with great interest the article by Steg et al 1 who report a subgroup analysis of the Occluded Artery Trial (OAT), 2 a randomized study comparing percutaneous coronary intervention (PCI) combined with medical therapy to medical therapy alone in patients with persistently occluded infarct related artery 3 to 28 days after an acute myocardial infarction, in which they assess the relation between angiographically visible collaterals to the infarct related artery territory and clinical outcome and the interaction between collaterals and treatment assignment on outcome.
The authors report that, although there is a trend toward a lower rate of the composite end point of death, reinfarction and hospitalization for severe congestive heart failure (New York Heart Association Class IV) among patients with collaterals, as compared to those without, the presence of visible collaterals is not an independent predictor of the composite end point in the overall population in multivariate analysis, and does not significantly affect the comparison between assigned treatments with regard to the primary end point or any of the individual end points. They conclude that revascularization decisions should not be based on the presence or grade of angiographic collaterals.
However, in the subgroup of patients with no visible collaterals (nϭ251, 11% of the total patient population), the incidence of nonfatal heart failure (New York Heart Association Class III or IV) in the PCI group was less than half that of patients receiving medical therapy alone (7.5% versus 16.3%), with a borderline statistically significant interaction between collaterals and treatment assignment, that disappeared after inclusion of fatal events, in the overall population. The authors hypothesize that an excess of fatal events in the PCI group, possibly due to the consequences of subsequent reocclusion of the recanalized infarct artery, might offset the potential benefit of PCI. However, the reported rate of reinfarction (6.9% versus 6.0%) and of death (16.1% versus 14.8%), does not appear to differ significantly between the PCI group and the medical therapy group, respectively. Further, it has not been reported how many reinfarctions and fatal events were related to target lesion and vessel revascularization, or disease progression in nonculprit vessels, to verify the authors' hypothesis.
In our opinion, the finding of a substantial reduction of repeat hospitalization for New York Heart Association Class III-IV heart failure in the PCI group, despite the small sample size of the subgroup without visible collaterals, together with comparable rates of hard endpoints in the PCI and medical therapy groups, represents an important signal regarding a potential beneficial effect of PCI that needs further pathophysiological investigation and clinical verification in future studies. The present study did not provide information on the function of visible collaterals, in particular whether they have a relation with the presence and extent of (inducible) myocardial ischemia and myocardial viability in the infarct related artery territory. Did patients with no visible collaterals present a higher extent of myocardial ischemia than those with collaterals, a situation where PCI might exert a beneficial effect on heart failure, through the removal of myocardial ischemia?
